Skin Disorders News

Lirentelimab improved disease control among patients with antihistamine-refractory chronic urticaria, according to results of an open-label, proof-of-concept study published in The Journal of Allergy and Clinical Immunology.

An international team of researchers has developed hair dyes that may be less likely to cause the allergic reactions in users that can occur with traditional dyes, according to a study published in ACS Sustainable Chemistry & Engineering.

Common allergic conditions are more prevalent among nonwhite populations, which are underrepresented in many studies. But multiple strategies can improve their recruitment and retention, improving the value of study results, experts wrote.

Adults with moderate-to-severe atopic dermatitis treated with dupilumab had fewer and shorter hospitalizations related to the skin condition, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

The FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe atopic dermatitis among patients aged 12 years and older, according to a press release.

Laxative exposure early in life was associated with later allergic disease development, including rhinitis, atopic dermatitis and asthma, according to a cohort study published in Annals of Allergy, Asthma & Immunology.

Women with a history of asthma, atopic dermatitis and allergic rhinitis before conception demonstrated increased risk for peripartum mental disorders, according to a study published in Clinical and Translational Allergy.

Allergy and asthma treatment improved this year as the FDA approved multiple medications for new treatment. Here are the top developments for 2021 as reported by Healio.

The FDA has approved tralokinumab for the treatment of moderate to severe atopic dermatitis, LEO Pharma announced in a press release.